Junliang Ma

First-line immune checkpoint inhibitors versus chemotherapy in delaying quality of life deterioration in advanced NSCLC: a systematic review and meta-analysis

Backgroud: Immune checkpoint inhibitors (ICIs) have transformed first-line treatment for advanced non–small-cell lung cancer (aNSCLC). While overall survival(OS) remains the primary endpoint, health-related quality of life (HRQoL) is a key patient-centered outcome. Time to deteri...